Establishment of T-helper type 2 clone-induced eosinophilia in mouse conjunctiva.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Establishment of T-helper type 2 clone-induced eosinophilia in mouse conjunctiva.

Exp Eye Res. 1999 Jul;69(1):69-74. Unique Identifier : AIDSLINE MED/99307112
Hamada M; Sawa K; Nakata K; Ophthalmic Research Division, Santen Pharmaceutical Co., Ltd.,; 8916-16 Takayama-cho, Ikoma-shi, 630-0101, Japan.

Abstract: Eosinophil infiltration is one of the aspects of the inflammatory response to an allergen. The aim of this study was to establish T-helper type-2 (Th2)-induced conjunctival eosinophilia in mice to evaluate the effect of anti-allergic drugs. Th2 clone, D10.G4.1. (D10) with its specific antigen, conalbumin was co-injected into conjunctival tissue in mice. At 3-6 hr after D10 injection, eosinophil and neutrophil recruitment into conjunctival tissue was observed. Cellular infiltration into conjunctival tissue reached a maximum level between 24-48 hr after D10 injection. The number of eosinophils which infiltrated after 24 hr was dose dependent on T cell injection titer from 1x10(4), 1x10(5)to 1x10(6)cells site-1. The ratio of eosinophils to neutrophils at 24 hr after D10 cell (1x10(5)cells site-1) injection was about 9 to 1. The eosinophil infiltration into conjunctival tissue was significantly reduced by the intraperitoneal administration of anti-IL-5 monoclonal antibody (100 micrograms animal-1). Anti-IL-4 monoclonal antibody (500 micrograms animal-1) partially inhibited eosinophilia. The combined inhibitory effect of anti-IL-4 and anti-IL-5 monoclonal antibodies was larger than the inhibitory effect of anti-IL-5 monoclonal antibody alone. In conclusion, a Th2-induced mouse conjunctival eosinophilia model was established in which D10 activation results in IL-4 and IL-5 release. These cytokines elicit eosiniophil infiltration. This response shows that the model will be effective for screening candidates of anti-allergic drugs. Copyright 1999 Academic Press.

Keywords: JOURNAL ARTICLE Animal Antibodies, Monoclonal/IMMUNOLOGY Clone Cells/IMMUNOLOGY Conjunctivitis, Allergic/*IMMUNOLOGY/PATHOLOGY *Disease Models, Animal Eosinophilia/*IMMUNOLOGY/PATHOLOGY Female Interleukin-4/IMMUNOLOGY Interleukin-5/IMMUNOLOGY Mice Mice, Inbred AKR Th2 Cells/*IMMUNOLOGY
991030
A99A0891

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .